Fig. 3. SUS treatment reduces different Aβ species.

Slides:

Advertisements

Similar presentations

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model by Gerhard Leinenga, and Jürgen Götz Sci Transl Med Volume.

Advertisements

Fig. 6. VitabridC12 inhibited cutaneous inflammation via the nuclear factor-κB signaling pathway. Protein extracts were prepared, and western blot analysis.

Volume 1, Issue 3, Pages (November 2015)

Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.

Volume 90, Issue 5, Pages (June 2016)

Analysis of brain and spinal cord of treated Gaa−/− mice and controls

S534 phosphorylation affects DNA binding and gene expression by NF-κB at late time points through regulation of p65 stability. S534 phosphorylation affects.

Western blot of Aβ42-specific antibody compared with 4G8 antibody.

TRAIL-induced formation from the preligand assembly complex to the DISC. A, normal brain and glioblastoma tissues were examined by immunoblotting using.

Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.

Fig. 4. Plaque-associated microglia and astrocytes and brain cytokines were altered in APP/PS1;C3 KO mice compared to APP/PS1 mice. Plaque-associated microglia.

Fig. 2. STUB1 destabilizes and ubiquitinates TF and mediates TF regulation by AHR. STUB1 destabilizes and ubiquitinates TF and mediates TF regulation by.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Volume 24, Issue 2, Pages (February 2016)

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 1. Establishing SUS in an AD mouse model.

Fig. 2 In vitro and preclinical study with 18F-MPG.

C266S laforin's effect on LD‐associated general defect in autophagy

Figure 2 The K19del mutation affects the expression and solubility of CHP1 The K19del mutation affects the expression and solubility of CHP1 (A) Western.

Glucose uptake and expression of thermogenesis markers are increased in the BAT of HFD-fed NprcAKO mice. Glucose uptake and expression of thermogenesis.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Erythroid differentiation of human CD34+ cells promoted by AVP

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.

Impaired in vitro adipogenic differentiation parallels elevated HDAC9 expression. Impaired in vitro adipogenic differentiation parallels elevated HDAC9.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion.

Colonization in tumor models and different modes of administration

Fig. 6 Metarrestin treatment reduces pre-RNA synthesis and Pol I occupancy at rDNA without changing rDNA chromatin states. Metarrestin treatment reduces.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

by Joan B. Mannick, Melody Morris, Hans-Ulrich P

The microchip-based drug delivery device and overview of study design

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2 L. lactis–derived lactic acid antagonizes V

Fig. 4 Activation of mitochondrial apoptosis pathway by n-HA.

by Yu Miyazaki, Xiaofei Du, Shin-ichi Muramatsu, and Christopher M

Western blot analysis of skin tissue from CJD and non-CJD patients

Statins enhance efficacy of venetoclax in blood cancers

Fig. 3 Active p38γ dissociates PSD-95/tau/Fyn/NR complexes.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 6. Microglial phagocytosis and lysosomal uptake of Aβ induced by SUS treatment. Microglial phagocytosis and lysosomal uptake of Aβ induced by SUS.

Fig. 4. SUS treatment rescues memory deficits in an AD mouse model.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 3 Mmp-2−/− mice are protected from obesity and leptin resistance.

Fig. 6 PPAR-γ is a direct target of Suv420h.

Fig. 4. Plaque-associated microglia and astrocytes and brain cytokines were altered in APP/PS1;C3 KO mice compared to APP/PS1 mice. Plaque-associated microglia.

Fig. 6. Confocal image series at 10-μm intervals through the full retinal thickness at P48 in WT and vldlr-null mice. Confocal image series at 10-μm intervals.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Fig. 3. HERV-K–induced neuronal toxicity in vivo.

Fig. 7 Heart-specific OMA1 down-regulation protects from hypertrophy induced by TAC. Heart-specific OMA1 down-regulation protects from hypertrophy induced.

Fig. 1. Establishing SUS in an AD mouse model.

Fig. 2. Col IV–Ac2-26 NPs increase subendothelial collagen in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26 NPs increase subendothelial.

Fig. 7. Altered morphology after ultrasound but unaltered numbers of microglia in SUS-treated mice. Altered morphology after ultrasound but unaltered numbers.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 3. Col IV–Ac2-26 NPs suppress lesional superoxide and increase lesional Il10 mRNA in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26.

Fig. 5. SUS treatment reduces Aβ in a second cohort of AD mice.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 2. SUS reduces Aβ plaques in an AD mouse model.

Presentation transcript:

Fig. 3. SUS treatment reduces different Aβ species. SUS treatment reduces different Aβ species. (A to D) Western blotting of extracellular-enriched (A) and Triton-soluble (B) fractions of the brains of the first cohort of APP23 mice with 6E10 and 4G8 anti-Aβ antibodies revealed a reduction in distinct Aβ species in both fractions in SUS-treated compared to sham-treated mice. These data are quantified in (C) and (D), respectively. The Western blots show significant reductions of HMW species, the 56-kD oligomeric Aβ*56 (*56) and trimeric Aβ (3-mer)/CTFβ, in the extracellular-enriched fraction and of *56 and 3-mer/CTFβ in the Triton-soluble fraction (unpaired t tests, P < 0.05). GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used for normalization. MWM, molecular weight marker. (E) ELISA for Aβ42 in the Triton-soluble fraction revealed a significant reduction in SUS-treated compared to sham-treated mouse brains (unpaired t test, P < 0.05; n = 10 per group). Gerhard Leinenga and Jürgen Götz Sci Transl Med 2015;7:278ra33 Copyright © 2015, American Association for the Advancement of Science